
    
      The objective of this study is to demonstrate the efficacy of 80 mg adalimumab monthly dosing
      compared with placebo as measured by ACR20 response criteria following 12 weeks of therapy.
      The study is also designed to demonstrate the non-inferiority of monthly dosing of 80 mg
      adalimumab compared with dosing of 40 mg adalimumab eow as measured by ACR20 response
      criteria at Week 12.
    
  